

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Oncology

**Manuscript NO:** 52557

**Title:** Circulating cytokines and outcome in metastatic colorectal cancer patients treated with regorafenib

**Reviewer's code:** 03551817

**Position:** Editorial Board

**Academic degree:** PhD

**Professional title:** Associate Professor, Associate Research Scientist

**Reviewer's country:** China

**Author's country:** Italy

**Manuscript submission date:** 2019-11-14

**Reviewer chosen by:** Artificial Intelligence Technique

**Reviewer accepted review:** 2019-11-15 15:31

**Reviewer performed review:** 2019-11-15 16:08

**Review time:** 1 Hour

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input checked="" type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input checked="" type="checkbox"/> Advanced
		<input checked="" type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

#### **SPECIFIC COMMENTS TO AUTHORS**

This is a valuable retrospective study. But the authors collected 17 blood samples of patients treated with regorafenib or 6 healthy volunteers, the samples are not enough. I suggest the authors collect more samples of patients and healthy volunteers. Meanwhile, the authors evaluate more cytokines such as ILs.

#### **INITIAL REVIEW OF THE MANUSCRIPT**

##### ***Google Search:***

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☒ No

##### ***BPG Search:***

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☒ No

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Oncology

**Manuscript NO:** 52557

**Title:** Circulating cytokines and outcome in metastatic colorectal cancer patients treated with regorafenib

**Reviewer's code:** 03004570

**Position:** Editorial Board

**Academic degree:** MD

**Professional title:** Professor

**Reviewer's country:** Turkey

**Author's country:** Italy

**Manuscript submission date:** 2019-11-14

**Reviewer chosen by:** Artificial Intelligence Technique

**Reviewer accepted review:** 2019-11-15 05:04

**Reviewer performed review:** 2019-11-17 19:22

**Review time:** 2 Days and 14 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input checked="" type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input checked="" type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

## **SPECIFIC COMMENTS TO AUTHORS**

This manuscript is a retrospective cohort study about the relationship between some circulating cytokines and the clinical outcome in mCRC patients treated with regorafenib. As the authors mentioned, this is a “proof of concept” study. The number of patients is very low but this is expected in forth and fifth line treatment in mCRC. They demonstrated that a cytokine signature may be predictive for the response to regorafenib, if validated in future trials. Avoiding ineffective treatments is a clinically important issue. I recommend some minor changes: How was the primary site of 9 colon cancer patients (right or left)? In the Discussion section, citation of references should be corrected as [17-19] and [20-22] in place of [17-18-19] and [20-21-22] respectively. Figures are informative and nice.

## **INITIAL REVIEW OF THE MANUSCRIPT**

### ***Google Search:***

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

### ***BPG Search:***

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No